SMARCB1 and ataxia telangiectasia: Firstly, the diagnosis of AT/RT mainly relied on morphological diagnosis and immunohistochemistry with internal review in most pathology departments; central pathological reviews and molecular confirmation of SMARCB1/SMARCA4 mutation/deletion status are not mandatory in Taiwan.